Giam Pharma International Sàrl is a Swiss-based biotech company committed to pioneering innovation in oncology.
Building on our deep experience in the therapeutic use of natural extracts, we have transitioned into advanced oncology drug development with a strong focus on safety, toxicity management, and patient quality of life.
Our lead asset, Fraisinib, is a first-in-class small molecule targeting GARS1, a metabolic enzyme overexpressed in aggressive tumors such as NSCLC and PDAC.
Preclinical studies show potent anti-tumor activity combined with low systemic toxicity.
We are currently preparing for GLP-compliant studies and early clinical phases, and we welcome collaboration with partners who share our vision for breakthrough cancer therapies.
Company Details
- Address
- Route De L'ile-Aux-Bois, Monthey,vallese 1870,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Cirié.
- HQ
- Monthey, Vallese
Giam Pharma Internationl Questions
Giam Pharma Internationl's website is https://www.giampharma.com/all-about-us
Giam Pharma Internationl's LinkedIn profile is https://ch.linkedin.com/company/giam-pharma-internationl
Giam Pharma Internationl's industry is
Biotechnology Research
Giam Pharma Internationl's top competitors are
Hippo Biosensors,
Holution Gmbh,
Medicell Company Ltd.,
Gxp Gmbh,
Govern,
Abiovet,
Tanawaa Trading Company,
Gelbhart Innovations,
Galepharm Ag,
Ibsa Group.
Giam Pharma Internationl's categories are Biotechnology Research
